Following his graduation in Pharmaceutical Sciences at the University of Freiburg in Germany, Dr. Witzigmann joined the University College London and the Division of “Molecular RNA Biology and Cancer” at the German Cancer Research Center (DKFZ) in Heidelberg. Dr. Witzigmann obtained his PhD in Pharmaceutical Technology at the University of Basel in Switzerland focusing on strategies to improve organ and cell type-specific drug delivery of nanomedicines. In 2018, Dr. Witzigmann joined the NanoMedicines Research Group at the UBC.
Currently, Dr. Witzigmann is a Principal Research Fellow in the NanoMedicines Research Group at the University of British Columbia (UBC) and Operational Lead for the Nanomedicines Innovation Network (NMIN) NanoCore Legacy Initiative within the newly established national Networks of Centres of Excellence (NCE) in Nanomedicine hosted at UBC. He is a Board Member of the “Gene Delivery and Genome Editing” Focus Group of the Controlled Release Society. In 2019, Dr. Witzigmann was awarded the prestigious Thudichum Award for his research on lipid nanoparticle technology and preclinical screening tools to facilitate LNP development.